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Some tumors are known to have a deﬁnite cause-eﬀect etiology, but renal cell carcinoma (RCC) is not one of them precisely. With
regard to RCC we can only try to identify some clinical and occupational factors as well as substances related to tumorigenesis.
Smoking, chemical carcinogens like asbestos or organic solvents are some of these factors that increase the risk of the RCC. Viral
infections and radiation therapy have also been described as risk factors. Some drugs can increase the incidence of RCC as well as
other neoplasms. Of course, genetics plays an outstanding role in the development of some cases of kidney cancer. Chronic renal
failure, hypertension, and dialysis need to be considered as special situations. Diet, obesity, lifestyle, and habits can also increase
the risk of RCC. The aim of this review is to summarize the well-deﬁned causes of renal cell carcinoma.
Copyright © 2008 D. Pascual and A. Borque. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Speaking about cancer, one of the most diﬃcult issues is to
ﬁnd a deﬁnite and direct cause. There are few tumors with a
well-known etiology, but renal cell carcinoma (RCC) is not
one of them precisely.
In these cases, we can only try to identify some clinical
and occupational factors, or some substances related to
carcinogenesis.
Epidemiology is an important tool to answer many
questionsaboutcancerorigin.Diﬀerencesinage,gender,and
geographic distribution have been reported, and multiple
clinical factors related to the development of RCC have
been established. Some of them have been thoroughly
demonstrated in experimental models and in vitro studies,
however not all of them recognized as deﬁnite etiologic
factors.
2. MATERIAL AND METHODS
A systematic review search strategy was developed to identify
publications related to epidemiology of renal cell carcinoma.
This search strategy was run in PubMed through the medical
subject heading “carcinoma, renal cell” and the subheading
of this descriptor “epidemiology.” We limited our search
strategytoarticlespublishedintheprevious5years,language
English or Spanish, and related to humans.
585 articles were found. Abstracts were evaluated and
the full text of articles selected was reviewed. Secondary
search from the bibliography of selected articles was also
considered.
The European cancer registry-based study on survival
and care of cancer patients (EUROCARE) and our experi-
ence was considered. Last review was on 31 of March 2008.
3. DEMOGRAPHIC ASPECTS OF
RENAL CELL CARCINOMA
Among urologic tumors, RCC takes the third place in
incidence, following prostate carcinoma and transitional cell
carcinoma of bladder.
Representing two percent of the adult malignancies [1],
this malignancy takes the tenth and fourteenth place among
men and women, respectively, with a man to woman ratio of
3/2 [2]; see Table 1.
The peak incidence occurs in the sixth decade, with 80%
of the cases within the 40 to 69-year-old population.
Althoughthemostfrequentrenaltumorinthechildhood
is the Wilms tumor, it is important to state that the
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Table 1: Epidemiologic features of the RCC.
3rd urologic tumor in incidence Maximum incidence on 6th
decade
2% of adults malignancies Male/Female ratio: 3/2
85–90% of adult renal
parenchymal malignancies
10th male malignancy and 14th
female malignancy
2–6% of child renal
malignancies
More frequent in afroamerican
people
Cancer speciﬁc mortality of
40% More frequent in urban people
Table 2: Geographic distribution of RCC [8].
Incidence Zones
High Denmark, New Zealand, Norway, Scotland
Moderate United States, Australia, Belgium, France, Holland
Low Spain, Ireland, Italy, Japan, Venezuela, India, China
children, without diﬀerences between sexes [3, 4]. Besides,
the incidence of both malignancies is similar in the second
decade of life. In these early ages the papillary diﬀerentiation
seems to be more frequent with higher tendency to present
a locally advanced and high-degree disease at the moment
of the diagnosis [5], However, when comparing stage by
stage with adult tumors, we ﬁnd a better response to surgical
treatment and higher survival rates, even with positive nodal
disease.
RCC represents 85 to 90% of renal parenchymal malig-
nancies [6, 7].
Among urologic tumors, it is the worst in cancer speciﬁc
mortality, since more than 40% of the patients with RCC
die of the disease, opposite to the 20% mortality observed
in prostate cancer or bladder carcinoma.
In United States 30000 new cases are diagnosed every
year, and approximately 12000 patients die of this disease,
with an incidence of near nine cases per 100000 inhabitants
per year. Afroamericans have 10 to 20% higher incidence,
and the reason is not completely understood [9].
Most of the cases of RCC are sporadic and only 4% are
familiar.TheestimatednumberofnewcasesintheEuropean
Union during 2006 was 63300, with 26400 deaths of RCC
[10]. The estimated survival in 5 years rises to 54% in males
and 57% in women [11].
Table 2 shows diﬀerent incidences of RCC in the world.
Since 1930 incidence of RCC has been increasing, mostly
between1930and1980.Withinthisperiodtheincidencealso
rose from 0.7 to 4.2 per 100000 per year in women and from
1.6 to 9.6 in men [12]. Since 1980 a sharp increase has not
been observed comparing to other genitourinary tumors or
other type of malignancies. Similarly, deaths caused by RCC
had been stable.
Variations of incidence within the ﬁrst period could be
explained by an easier diagnosis, as a result of diﬀusion and
routineuseofdiagnostictoolssuchasultrasoundorCTscan,
and not due to a real increased incidence of RCC.
Table 3: Some etiologic factors of RCC [15].
Etiologic factor Relative risk (C.I. 95%)
Von Hipple-Lindau disease 100 (not available)
Chronic dialysis 32 (not available)
Obesity 3.6 (2.3–5.7)
Smoking 2.3 (1.1–5.1)
First relative with RCC 1.6 (1.1–2.4)
Hypertension 1.4 (1.2–1.7)
Dry cleaners 1.4 (1.1–1.7)
Diuretics 1.3 (1.07–1.52)
Trichloroethylene 1 (0.7–9.66)
Radiation therapy 1.1 (3.2–8.1)
Phenacetin 1.1 (2.6–6)
Polycystic kidneys 0.8 (2–4.5)
Cadmium exposure 1 (2–3.9)
Arsenic exposure 1.6 (2.3–4.1)
Asbestos exposure 1.1 (1.4–1.8)
ItisalsoimportanttostatethatRCCisfoundincidentally
in 1.5% of the autopsies [13].
RCC is more frequent in urban populations rather
than in rural ones. This observation may be explained by
the sanitary conditions and the smoking habit in urban
populations. However it has not been related neither to
socioeconomic nor to educational status [14].
There are multiple factors related to the development of
RCC; see Table 3. Some of them have been demonstrated in
experimental models and in vitro studies, however not all of
them can be considered as deﬁnite etiologic factors.
Herein, we describe these main factors.
3.1. Smoking
Multiple carcinogenic substances have been identiﬁed in
tobacco and related to a variety of neoplasms at diﬀerent
levels. A high incidence of RCC in smokers has been shown
[16], estimated in 2.3 fold risk ratio, directly related with the
number of cigarettes and inversely with age of beginning of
the habit. Likewise it has been shown that the carcinogen
dimetilnitrosamine induces this neoplasm in experimental
studies. Some authors reported that smokers’ risk for RCC
compares to nonsmokers’ after the ﬁfth year of nonsmoking,
but a meta-analysis made by Hunt showed that only after ten
years the risk can be similar in both groups [17], depending
onthedose oftobaccoinhaled.AnotherstudybyMcLaughin
[18] and Lipworth [19] conﬁrmed tobacco as the most
important risk factor for renal cancer, detected in 20% of the
cases of RCC.
But smoking is not only important in the genesis of
RCC, and prognostic nomograms have also been developed
[20]. A multivariate study carried out in “Miguel Servet”
University Hospital of Zaragoza, Spain (in press), smoking
habit increases 2.84 fold (1.27–6,32) the risk of progression
of the disease after surgery [21], similarly to previous studies
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3.2. Chemicalcarcinogens
Some radiological contrasts have been associated with an
increased incidence of RCC [22]. Although Cycasin (a
substance derived from a palm fruit that grows in the island
of Guam) induces RCC in animals, a higher incidence of this
neoplasm within the island population could not be shown.
Cadmium was demonstrated to have inﬂuence on the
development of RCC in smokers [23, 24].
(i) Asbestos. A signiﬁcantly elevated mortality rate for
kidney cancer has been reported in two cohort
studies, on insulation workers [25]a n do na s b e s t o s
products workers [26]. Autopsy surveys and animal
studies indicate that asbestos ﬁbers can be deposited
in kidney tissue.
(ii) Organic solvents. Pesticides, copper sulphate, benzi-
dine, benzene herbicides, and vinyl chloride have
been found as risk factors of RCC in prolonged
exposure. A dose dependent eﬀect has been seen only
for organic solvents and copper sulphate [27, 28].
Recent reviews of cohort studies found little or no
evidence of an increased risk for RCC among people
exposed to gasoline and petroleum derived products
[29, 30].
(iii) Polycyclic aromatic hydrocarbons. Workers exposed to
high levels of polycyclic aromatic hydrocarbons like
coke and coal oven workers, ﬁreﬁghters, asphalt, and
tar have been reported to be at increased risk for
kidney cancer.
3.3. Radiation
Ionizing radiation appears to increase the RCC risk slightly,
especially among patients treated for ankylosing spondylitis
and cervical cancer [31]. An increased risk has also been
reported for patients receiving radium 224 for bone tuber-
culosis and ankylosing spondylitis [32].
3.4. Viruses
The immunosuppressant state related to the HIV infection
determines that prevalence of RCC in the infected popu-
lation rises 8.5 times compared to the prevalence of the
noninfected ones.
The inﬂuence of the polyomavirus SV 40 and of the
adenovirus 7 has also been detected in experimental studies.
A clear-cut association was found between herpes-type
virus and renal tumors in toads. These ﬁndings led to search
for evidence of herpes virus proteins in human tumors as
well. Although herpes simplex proteins were found in only
one study [33, 34], these ﬁndings need to be conﬁrmed by
further research.
3.5. Diuretics
This type of drugs which inhibits water reabsorption on
the renal tubule cells seemed to be responsible for a higher
incidence of RCC in patients with chronic intake of diuretics
[35, 36]. Even though, it is noteworthy that hydrochloroth-
iazide and furosemide (both eﬀective at the renal tubule
level) induce tubular cell adenomas and adenocarcinomas of
the kidney in rats [37]. But Yuan [38] showed in his study
that an adequate use of diuretics for treating hypertension
eliminates the risk associated with the above mentioned
drugs, diﬀerentiating the inﬂuence of hypertension as a risk
factor for RCC rather than diuretics.
3.6. Analgesics
This is a controverted topic. Several studies reported an
increased incidence of RCC in patients with chronic intake
of analgesics like paracetamol, salicylates, or phenacetin [39,
40], however in other studies this relationship has not been
conﬁrmed neither for time of consumption nor for dose of
the drug taken [41].
Although a heavy use of drugs containing phenacetin has
beenclearlydemonstratedtoincreasetheriskfortransitional
cancer of the renal pelvis, the association with RCC is
much weaker. On the other hand, an increased risk of RCC
associated with aspirin or acetaminophen consumers was
observed[42],butothersbelievethatneitheracetaminophen
norotheranalgesicshavebeenconvincinglylinkedwithRCC
[19].
3.7. Oestrogens(dietilestilbestrol)
Although oestrogens can induce RCC in the animal model,
little evidence supports an association of the disease with
oestrogens in humans [43] and only weak relation has been
reported for the use of oestrogens after menopause and for
oral contraceptives [44].
3.8. Inheritance
Most of the cases of RCC are sporadic; however there are
some deﬁned types of RCC with a hereditary pattern [45].
(1)VonHippel-Lindau(VHL)disease
The VHL disease is inherited through an autosomal domi-
nant trait. The syndrome is caused by germline mutations
of the VHL tumor suppressor gene, located on chromosome
3p25-26; these mutations can virtually always be identiﬁed
[46]. The VHL protein takes part in cell cycle regulation and
angiogenesis [47]. Patients develop capillary haemangioblas-
tomas of the central nervous system and retina, clear cell
carcinoma, phaeochromocytoma, pancreatic, and inner ear
tumors.
The clinical diagnostic criteria of VHL disease consist of
(i) presence of capillary haemangioblastoma in the cen-
tral nervous system or retina,
(ii) presence of one of the typical VHL associated
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Fourty to sixty percent of the patients with VHL disease
present an RCC. Although they are usually low-grade
tumors, the progress rate to metastasis is around 30% [48].
Renal lesions in carriers of VHL germline mutations are
either cysts or clear cell RCC. They are typically multifocal
and bilateral.
(2)Hereditarypapillaryrenalcarcinoma
Thistypeofrenalcarcinomaisaninheritedtumorsyndrome
with autosomal dominant trait and of late onset, with
multiple and bilateral papillary renal cell carcinomas type 1.
The disease is caused by activating mutations of the MET
oncogene which maps the chromosome 7q31.
(3)Hereditaryleiomyomatosisandrenalcellcarcinoma
This is an autosomal dominant tumor syndrome with
germline mutations in the FH gene (chromosome lq42.3–
q43), These patients have the tendency to acquire benign
leiomyomas of the skin and the uterus, and occasionally
papillary renal cell carcinoma type 2 and uterine leiomyosar-
comas.
(4)Birt-Hogg-Dubesyndrome
This syndrome is characterized by benign skin tumors,
speciﬁcally ﬁbrofolliculomas, trichodiscomas, and acrochor-
dons. Multiple renal tumors and spontaneous pneumotho-
races are also frequent. We can ﬁnd chromophobe RCC, typ-
ical RCC, hybrid oncocytoma, papillary RCC, or oncocytic
tumors.
The Birt-Hogg-Dube gene maps the chromosome
17p11.2 and encodes the protein called folliculin. This gene
is also involved in sporadic RCC [49].
(5)Familiarclearcellrenalcellcarcinoma
Thesefamiliespresentahereditaryformofmultiple,bilateral
clear cell RCC but without any clinical evidence of suﬀering
the von Hippel-Lindau disease.
Thishereditarycancerischaracterizedtopresenttranslo-
cations aﬀecting the chromosome 3. Translocations have
been described among the chromosome 3 and the chromo-
somes 8 [50], 6 [51, 52], 2 [53, 54], 1 [55], and 4 [48].
3.9. Acquiredcysticdisease/chronicdialysis
Approximately the 35 to 47% of the patients on dialysis and
specially those with a very long history present acquired
cystic disease. Some patients with this disease develop a
papillary hyperplasia in the epithelium of the cysts that
would be the origin of the RCC [56, 57].
Approximately the 5 to 9% of the patients with acquired
cystic disease will develop an RCC [58], showing a higher
incidence than the general population. As such, we suggest
a close follow-up in the kidney-transplant population, and
therefore the immune-suppressed individuals who are on
dialysis for a long time, due to a high risk of developing RCC.
3.10. Dietandobesity
Hypercaloric diet and obesity seem to be associated with a
higher risk for suﬀering of RCC. Obesity accounts for about
30% of renal cancers [19].
Some studies relate a higher incidence of RCC with high
body mass index. The relative risk was found to be 3.3 in
males and 2.3 in females [59].
The mechanism of obesity to cause kidney cancer is
not clear. Hormonal changes such as increased levels of
endogenous oestrogens in the obese may be the mechanism
through which oestrogens induce renal cancer as observed
in animal models. However, there is scant epidemiologic
evidence supporting hormonal carcinogenesis regarding
RCC. Obesity may also predispose to arterionephrosclerosis,
which may render the renal tubules more susceptible to car-
cinogens. Elevated cholesterol levels associated with obesity
mightalsoplayarole,assuggestedbyanimalstudiesshowing
that cholesterol-lowering drugs provide some protection
against RCC. Cholesterol and other lipids may favour tumor
development by an inhibitory eﬀect on immune cells.
Low vitamin D level, which is usually present in obese
patients, may predispose to acquire RCC. This vitamin is
known to have inhibitory eﬀects on the growth of RCC cell
lines in vitro [60].
Finally, Lipworth [19] reported that the only consistent
protective factor is consumption of fruit and vegetables.
3.11. Coffee,alcohol,andotherbeverages
Case-control studies have not conﬁrmed the suggested
relationship between kidney cancer and consumption of
coﬀee, when adjusting the smoking variable. Although two
studies have suggested a positive association, a two-fold
increased risk in both sexes was associated with the use of
decaﬀeinated coﬀee. In another study, an increased risk of
RCC was found only among women with regular coﬀee
intake [61]. No dose-dependent risk was reported in either
study.
On the other hand, a signiﬁcant lower risk was reported
in Norway among consumers of seven or more cups of
coﬀee compared to those who drink two or fewer cups
daily, representing a relative risk of 0.25 [62]. Review studies
indicate that coﬀee consumption does not increase RCC
risk.
Few studies have shown an increased risk of RCC among
tea women consumers [63]. Another study has found a dose-
response relationship between tea consumption and kidney
cancer mortality [64]. The etiologic signiﬁcance of these
ﬁndings in direct relationship with tea tannins is not clear
[65].
The association between alcoholism and kidney cancer
mortality has not been demonstrated by well-deisgned
studies [66]. In fact, a recent case-control study found a
statistically signiﬁcant inverse association between alcohol
consumption and RCC risk [67]. No increase in mortality
from kidney cancer has been reported either within alcoholic
patients or brewery workers [68].D. Pascual and A. Borque 5
3.12. Physicalactivity
A moderate recreational activity reduces the risk of renal
cancer both in men and women. The mechanism is not clear,
but there is no doubt that energy expenditure is one of the
major determinants for obesity, which is a strong risk factor
for RCC.
3.13. Hypertension
Hypertension seems to be signiﬁcant for the development of
kidney cancer. The strength of this relationship is reduced
with the use of diuretics and other antihypertensive drugs,
regardless of some of these drugs have been associated with
RCC risk. The main problem consists to identify whether
the increased risk is due to hypertension or antihypertensive
medications.
Despite the mechanism for hypertension to cause renal
cancer is not completely understood [69] it seems that
metabolicand/orfunctionalchangesintherenaltubularcells
produce carcinogenesis. Wide case-control studies have only
found a slight relation between RCC and hypertension [70].
Further studies are needed.
3.14. Alterationsindevelopmentofthekidney
The anomalous development of the kidneys may act as a
teratogenic factor.
In horseshoe kidneys, the area of the isthmus is prone to
develop tumors [71], due to an anomalous migration of the
cells toward this area. However, although the most frequent
tumor developed in this malformation is the RCC, the
incidence remains identical to that of the general population,
without diﬀerences in evolution or prognosis [72].
In conclusion we can aﬃrm that respect RCC, like in
other malignant diseases, ethiology, and risk factors are
not completely understood. There is some evidence that
certain situations, drugs, habits, or genetics are related to
the development of renal cancer, but several studies found
controversial results and diﬀerent degrees of evidence.
Smoking and obesity seem to be the most important
independent risk factors in the genesis of RCC, reported by
diﬀerent authors.
Chromosomal mutations were clearly identiﬁed in the
context of well-deﬁned hereditary diseases.
The adequate use of diuretics and analgesics may be
recognized as protective factors not only for RCC but for
other diseases as well.
General healthy habits like limiting alcohol and coﬀee
intake, decreasing the number of cigarettes, lowering fat
consumption, keeping a suitable weight, and practicing
regular exercise may reduce the risk and indicence of RCC.
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